-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Kymera Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2019 to Q2 2025.
- Kymera Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2025 was -$84.6M, a 66% decline year-over-year.
- Kymera Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2025 was -$312M, a 68.1% decline year-over-year.
- Kymera Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$262M, a 58.1% decline from 2023.
- Kymera Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$166M, a 2.65% decline from 2022.
- Kymera Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$161M, a 60.4% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)